Today’s pharmaceutical industry is teetering between an innovation renaissance and an affordability crisis. Investment analyst Craig Gordon, a former practicing physician, takes us inside the complex world of pharma and biotech, where the interests of doctors, patients, insurers and policymakers can often be at odds. Listen and learn: What made 2016 an off year for pharma investors What leading-edge innovations are shaping the industry today, and what sorts of companies stand to benefit Why pharma’s next big innovation just might be affordability Your host, Matt Miller, is the policy and communications advisor for Capital Group. An author and former Washington Post columnist, Matt was co-host of the public radio program Left, Right & Center. Do you have any topics for Capital Ideas? Please contact our editorial team at CapitalIdeas@capgroup.com. Related Global Companies: The Power of Deep Distribution Networks